Premium
P4‐314: Discordance Between Amyloid‐PET and CSF Amyloid‐β for Diagnosing Alzheimer’S Disease in a Clinical Setting
Author(s) -
Niemantsverdriet Ellis,
Van den Bossche Tobi,
Van Mossevelde Sara,
Ottoy Julie,
Verhaeghe Jeroen,
Somers Charisse,
De Roeck Ellen Elisa,
Struyfs Hanne,
Deleye Steven,
Goeman Johan,
Versijpt Jan,
Paul de Deyn Peter,
Mariën Peter,
Wyffels Leonie,
Bjerke Maria,
Ceyssens Sarah,
Stroobants Sigrid,
Staelens Steven,
Engelborghs Sebastiaan
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.07.057
Subject(s) - dementia , medicine , concordance , atrophy , pathology , cerebrospinal fluid , alzheimer's disease , amyloid (mycology) , pittsburgh compound b , lumbar puncture , disease
sion analysis. Conclusions:The candidate CRMs were found to be commutable for all method comparisons. After the value assignment is completed, the CRMs will be released and can be used by the IVD manufacturers to recalibrate their assays as mandated in the EU Directive on In Vitro Diagnostics Medical Devices (Directive 98/79/EC). The release of the materials should improve the concordance of measurement results between different analytical platforms and will allow the establishment of a global diagnostic cutoff value for Ab42 in CSF that can be used for the diagnosis of AD.